Charlson comorbidity index predicts outcomes of elderly after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome

Chien, Sheng-HsuanSheng-HsuanChienMING YAOLi, Chi-ChengChi-ChengLiChang, Ping-YingPing-YingChangYu, Ming-SunMing-SunYuHuang, Cih-EnCih-EnHuangTan, Tran-DerTran-DerTanLin, Cheng-HsienCheng-HsienLinYeh, Su-PengSu-PengYehLi, Sin-SyueSin-SyueLiWang, Po-NanPo-NanWangLiu, Yi-ChangYi-ChangLiuGau, Jyh-PyngJyh-PyngGau2023-03-272023-03-272021-120929-6646https://scholars.lib.ntu.edu.tw/handle/123456789/629788Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the curative therapy for acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS), but advanced age with multiple comorbidities limits the eligibility for allo-HSCT. We conducted a retrospective study to investigate the comorbidities assessments and prognostic factors that predict outcomes for these patients.enAcute leukemia; Allogeneic hematopoietic stem cell transplantation; Charlson comorbidity index; Elderly adult; Myelodysplastic syndromeCharlson comorbidity index predicts outcomes of elderly after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndromejournal article10.1016/j.jfma.2020.12.021334238992-s2.0-85099131049https://api.elsevier.com/content/abstract/scopus_id/85099131049